Daniel D. Astridge

Daniel D. Astridge

Auto-generated profile, based on publicly available information

Daniel D. Astridge

Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 East Montview Boulevard, Aurora, Colorado 80045, United States

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in ACS Energy Letters
Verified
Journal Article
Closed access
JWJiantao Wang
Jiantao Wang
ZYZhenhua Yu
Zhenhua Yu
DADaniel D. Astridge
Daniel D. Astridge
ZNZhenyi Ni
Zhenyi Ni
LZLiang Zhao
Liang Zhao
JHJinsong Huang
Jinsong Huang

18 May 2023 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ZXZhaojian Xu
Zhaojian Xu
DADaniel D. Astridge
Daniel D. Astridge
RKRoss A. Kerner
Ross A. Kerner
XZXinjue Zhong
Xinjue Zhong
JHJunnan Hu
Junnan Hu
BRBarry P. Rand
Barry P. Rand

23 May 2023 in Nano Letters
Verified
Journal Article
Closed access
LZLianfeng Zhao
Lianfeng Zhao
DADaniel D. Astridge
Daniel D. Astridge
WGWilliam B. Gunnarsson
William B. Gunnarsson
ZXZhaojian Xu
Zhaojian Xu
JHJisu Hong
Jisu Hong
BRBarry P. Rand
Barry P. Rand

29 January 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
JSJuliet E. Strang
Juliet E. Strang
DADaniel D. Astridge
Daniel D. Astridge
VNVu T. Nguyen
Vu T. Nguyen
PRPhilip Reigan
Philip Reigan
AMP-activated protein kinase (AMPK) is a central mediator of cellular metabolism and is activated in direct response to low ATP levels. Activated AMPK inhibits anabolic pathways and promotes catabolic activities that generate ATP through the phosphorylation of multiple target substrates. AMPK is a therapeutic target for activation in several chronic metabolic diseases, and there is increasing interest in targeting AMPK activity in cancer where it can act as a tumor suppressor or conversely it can support cancer cell survival. Small molecule AMPK activators and inhibitors have demonstrated some success in suppressing cancer growth, survival, and drug resistance in preclinical cancer models. In this perspective, we summarize the role of AMPK in cancer and drug resistance, the influence of the tumor microenvironment on AMPK activity, and AMPK activator and inhibitor development. In addition, we discuss the potential importance of isoform-selective targeting of AMPK and approaches for selective AMPK targeting in cancer.

5 July 2022 in ACS Applied Energy Materials
Verified
Journal Article
Closed access
JHJacob B. Hoffman
Jacob B. Hoffman
DADaniel D. Astridge
Daniel D. Astridge
SPSo Yeon Park
So Yeon Park
FZFei Zhang
Fei Zhang
MYMengjin Yang
Mengjin Yang
ASAlan Sellinger
Alan Sellinger

12 August 2025 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
VNVu Nguyen
Vu Nguyen
CCCaleb Chandler
Caleb Chandler
JSJuliet E. Strang
Juliet E. Strang
DADaniel D. Astridge
Daniel D. Astridge
PRPhilip Reigan
Philip Reigan
Recent developments around inhibitors of the 90 kDa ribosomal S6 serine/threonine kinases (RSK1–4) have been focused on the optimization of known pan-RSK inhibitors such as SL0101 and BI-D1870. The RSKs are an intriguing target for cancer therapy due to their role as downstream effectors in the MAPK pathway. Herein, we focus on the utilization of computational modeling in inhibitor screening and development for RSK, and we examine computational artifacts in molecular modeling, quantum mechanical calculations, molecular dynamics, and high throughput screening. Variation between RSK structural models is also evident, given the available crystal structures, and liberties in homology modeling and dynamic conformations may capture new targeting approaches for these proteins. Furthermore, pan-kinase inhibitors are often used to target RSK since the four different RSK isoforms share a high degree of homology; however, they have distinct biological actions in cancer. A majority of RSK modeling generalizes the conclusions from one isoform onto the others; therefore, forming accurate isoform specific models containing their subtle differences will be key to the development of isoform-selective inhibitors. This review consolidates existing RSK models and the isoform specific structural differences that have and have not been considered, evaluates inhibition studies that have started to build upon RSK selectivity, including for its isoforms, and assesses other inhibitory binding sites to offer potential pathways forward. The leveraging of these differences through computational methods aims to guide next-generation isoform-selective RSK inhibitors.